Cargando…

Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma

PURPOSE: Pancreatic cancer is an aggressive solid tumor with a severe prognosis. Although tumor biomarkers are often used to identify advanced pancreatic cancer, this is not accurate, and the currently used biomarkers are not indicative of prognosis. The present study evaluated circulating tumor DNA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Shasha, Deng, Guochao, Sun, Jingjie, Han, Quanli, Lv, Yao, Xue, Tianhui, Ding, Lijuan, Yang, Tongxin, Qian, Niansong, Dai, Guanghai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446234/ https://www.ncbi.nlm.nih.gov/pubmed/36081557 http://dx.doi.org/10.3389/fonc.2022.926260

Ejemplares similares

Preoperative CA19-9 levels predict disease-free survival and overall survival in pancreatic adenocarcinoma patients after resection
por: Guan, Shasha, et al.
Publicado: (2019)

S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study
por: Shi, Yan, et al.
Publicado: (2022)

The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy
por: Gou, Miaomiao, et al.
Publicado: (2021)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
por: Gou, Miaomiao, et al.
Publicado: (2022)

Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection
por: Zhou, Qian, et al.
Publicado: (2023)

Survival of patients with advanced pancreatic cancer after iodine(125) seeds implantation brachytherapy: A meta-analysis
por: Han, Quanli, et al.
Publicado: (2017)

Retinoic Acid-Induced 2 (RAI2) Is a Novel Antagonist of Wnt/β-Catenin Signaling Pathway and Potential Biomarker of Chemosensitivity in Colorectal Cancer
por: Zhang, Weitao, et al.
Publicado: (2022)

Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
por: Song, Byeong Geun, et al.
Publicado: (2021)

Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma
por: Huang, Jiacheng, et al.
Publicado: (2021)

Paired box 5 increases the chemosensitivity of esophageal squamous cell cancer cells by promoting p53 signaling activity
por: Zhang, Weiwei, et al.
Publicado: (2022)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial
por: Shi, Yan, et al.
Publicado: (2017)

A Composite Biomarker of Derived Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio Correlates With Outcomes in Advanced Gastric Cancer Patients Treated With Anti-PD-1 Antibodies
por: Pan, Yuting, et al.
Publicado: (2022)

PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis
por: Gou, Miaomiao, et al.
Publicado: (2021)

AQP5 Is a Novel Prognostic Biomarker in Pancreatic Adenocarcinoma
por: Chen, Guo, et al.
Publicado: (2022)

Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score
por: Pan, Yuting, et al.
Publicado: (2022)

Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma
por: Reni, Michele, et al.
Publicado: (2020)

Pretreatment platelet to lymphocyte ratio is predictive of overall survival in metastatic pancreatic ductal adenocarcinoma
por: Li, Wanwan, et al.
Publicado: (2019)

The enigmatic helicase DHX9 as a candidate prognostic biomarker for resected pancreatic ductal adenocarcinoma
por: Chen, Le-gao, et al.
Publicado: (2022)

Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer
por: Kirchweger, Patrick, et al.
Publicado: (2022)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
por: Yu, Kenneth H., et al.
Publicado: (2021)

Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer
por: Huang, Lei, et al.
Publicado: (2023)

Identification of LncRNA Prognostic Signature Associated With Genomic Instability in Pancreatic Adenocarcinoma
por: Zhu, Jinfeng, et al.
Publicado: (2022)

Portal Venous Circulating Tumor Cells Undergoing Epithelial-Mesenchymal Transition Exhibit Distinct Clinical Significance in Pancreatic Ductal Adenocarcinoma
por: Pan, Yujin, et al.
Publicado: (2021)

Differential O- and Glycosphingolipid Glycosylation in Human Pancreatic Adenocarcinoma Cells With Opposite Morphology and Metastatic Behavior
por: Zhang, Tao, et al.
Publicado: (2020)

Development and Validation of a Simple-to-Use Nomogram to Predict Early Death in Metastatic Pancreatic Adenocarcinoma
por: Zhang, Zhong, et al.
Publicado: (2021)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival
por: Amantini, Consuelo, et al.
Publicado: (2019)

Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival
por: Botrus, Gehan, et al.
Publicado: (2022)

Machine learning-featured Secretogranin V is a circulating diagnostic biomarker for pancreatic adenocarcinomas associated with adipopenia
por: Jo, Yunju, et al.
Publicado: (2022)

Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma
por: Sutera, Philip A., et al.
Publicado: (2018)

Machine-learning based investigation of prognostic indicators for oncological outcome of pancreatic ductal adenocarcinoma
por: Chang, Jeremy, et al.
Publicado: (2022)

Development of a Nomogram to Predict Disease-Specific Survival for Patients After Resection of a Non-Metastatic Adenocarcinoma of the Pancreatic Body and Tail
por: Zou, Yiping, et al.
Publicado: (2020)

Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma
por: Yang, Chengkun, et al.
Publicado: (2019)

A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma
por: Zhou, Chenhao, et al.
Publicado: (2019)

Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Jiang, Jiahong, et al.
Publicado: (2021)

Establishment of a 4-miRNA Prognostic Model for Risk Stratification of Patients With Pancreatic Adenocarcinoma
por: Gong, Xun, et al.
Publicado: (2022)

A four oxidative stress gene prognostic model and integrated immunity-analysis in pancreatic adenocarcinoma
por: Wang, Hao, et al.
Publicado: (2023)

Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma
por: Park, Hyung Soon, et al.
Publicado: (2016)

Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy
por: Gou, Miaomiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5sv3r3i8n483pftvi32h6g369i